Octagon Capital Advisors’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Octagon Capital Advisors’s Portfolio GRCL Stock Details GRCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-596,611	Closed	-$5.99M	–	66
2023 Q4	$5.99M	Buy	+596,611	New	+$2.71M	0.96%	22

Octagon Capital Advisors's GRCL Position: Q1 2024 in Review

Octagon Capital Advisors sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q1 2024, closing a stake of 596,611 shares — an estimated $5.99M sold.

Octagon Capital Advisors first reported a position in GRCL in Q4 2023 and held it in 1 quarter. The position peaked at $5.99M in Q4 2023. 0 funds tracked by Wall St. Rank hold GRCL as of Q1 2024.

Octagon Capital Advisors reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q1 2024 after selling out during the quarter.
Octagon Capital Advisors sold 596,611 Gracell Biotechnologies Inc. American Depositary Shares shares in Q1 2024, an estimated $5.99M.
Octagon Capital Advisors first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q4 2023 and held it in 1 quarter.
Octagon Capital Advisors's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $5.99M in Q4 2023.
0 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q1 2024.

Based on Octagon Capital Advisors's 13F filing for Q1 2024, filed 15 May 2024.